[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646641":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"First Affiliated Hospital of Guangxi Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational Group",null,"Third-generation EGFR-TKI adjuvant therapy for Chinese patients with stage IA EGFR-positive NSCLC who have high-risk factors",[13],"Drug: Third-generation EGFR-TKI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Third-generation EGFR-TKI","This is an observational, non-interventional study. The interventions listed herein refer to routine standard adjuvant therapies administered entirely at the discretion and implementation of the attending physicians, without any interference from the study protocol. The research team is solely responsible for observing and collecting data, and does not participate in or influence patients' treatment decisions.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Nuo Yang, Prof.","CONTACT","+86-0771-5356708","yangnuogxmu@163.com",[27],{"facility":28,"status":10,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Affiliated Hospital of Guangxi Medical University","Nanning","Guangxi","530021","China","CN",{"type":35,"coordinates":36},"Point",[37,38],108.31667,22.81667,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":10,"email":25},"Nuo Yang",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100646641","a-non-interventional-real-world-study-on-the-adjuvant-treatment-of-chinese-egfr-positive-stage-ia-nsclc-patients-with-high-risk-factors-using-third-generation-egfr-tkis-100646641",false,"NCT07686185","A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.","A Non-interventional, Real-World Study of Third-Generation EGFR-TKI Adjuvant Therapy in Chinese EGFR-Positive Stage IA Non-Small Cell Lung Cancer Patients With High-Risk Factors","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Patients with IA-stage (8th edition of AJCC staging) non-small cell lung cancer (NSCLC) confirmed by histopathology and with high-risk factors\n3. EGFR mutation positive\n4. No previous systemic anti-tumor treatment\n5. Expected or already received surgical treatment\n6. Intended to receive or already received third-generation EGFR-TKI adjuvant therapy after surgery.\n\nExclusion Criteria:\n\n1. Small cell lung cancer\n2. With other malignant tumors that require treatment\n3. Pregnant or lactating women\n4. Those who the researchers consider not suitable to participate in this clinical trial.","ALL","18 Years",{"count":55,"type":56},500,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to evaluate the real-world effectiveness and safety of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-such as osimertinib, aumolertinib, and furmonertinib-as adjuvant therapy for patients with early-stage non-small cell lung cancer (NSCLC) in China.\n\nApproximately 500 eligible patients are planned to be enrolled. All participants must have been diagnosed with Stage IA NSCLC (according to the 8th edition of the AJCC staging system) following surgical resection, harboring EGFR-sensitive mutations, and presenting with high-risk recurrence factors (e.g., poor differentiation, lymphovascular invasion, and spread through air spaces).\n\nThis is a non-interventional, real-world study that does not alter physicians' original prescribing habits or clinical management strategies. Patients will receive standard treatment with third-generation EGFR-TKIs according to routine clinical practice (typically for a duration of three years). The research team will periodically collect follow-up data, with a primary focus on postoperative disease-free survival (DFS) and drug safety profiles.\n\nThrough this investigation, we seek to determine whether this specific population of high-risk early-stage patients can derive clinical benefit from postoperative targeted therapy. The findings are expected to provide evidence to support the development of future clinical guidelines.",[61,62],"Non-Small Cell Lung Cancer","Adjuvant Therapy",[61,64,65,66,17],"EGFR Mutation","Stage IA","High-risk Factors","NOT_YET_RECRUITING","2026-06-30",{"date":70,"type":71},"2026-07-07","ACTUAL",{"date":73,"type":56},"2026-09-01",{"date":75,"type":56},"2032-12-31",{"name":5,"class":6},1]